Despite the expression of these favourable prognostic markers, the overall prognosis for ILC is comparable to other types of breast cancer owing to resistance to hormone receptor antagonists and low chemotherapeutic responsiveness22,23. This evidence concerns the gene NR4A1 and breast cancer.